Post

Another setback for Minerva’s schizophrenia treatment roluperidone

On February 27, Minerva Neurosciences announced that it received a complete response letter (CRL) from the FDA regarding the company’s …

Sustainability challenges in rare disease trials remain, but change is happening

All clinical trials encounter difficulties along the way but rare disease trials have a variety of complexities which can make …

Rheumatoid arthritis in 2024: Navigating the global clinical trial landscape

Predicted to affect 1% of the world’s population by 2050, global Rheumatoid Arthritis (RA) cases will experience a significant 80.2% …

Takeda’s Eohilia to compete Sanofi’s Dupixent in eosinophilic oesophagitis treatment

The recent groundbreaking approval of Takeda’s Eohilia for patients 11 and older by the US Food and Drug Administration (FDA) …

Comorbidities associated with ADHD present an opportunity for pipeline products

Attention deficit hyperactivity disorder (ADHD) is a clinically heterogeneous disorder, with published research often putting comorbidity estimates at between 60%–80%. …